References
- Pullar T, Capell H A, Sulphasalazine. A “new” antirheumatic drug. Br J Rheumatol 1984; 23: 26–34
- Das K M, Rubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976; 1: 406–25
- Pullar T, Hunter J A, Capell H A. Which component of sulphasalazine is active in rheumatoid arthritis?. Br Med J 1985; 290: 1535–8
- Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977; 2: 892–5
- Wood D D, Ihrie E J, Hamerman D. Release of interleukin-1 from human synovial tissue in vitro. Arthritis & Rheumatism 1985; 28: 853–62
- Nouri A ME, Panayi G S, Goodman S M. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295–302
- Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183–92
- Remvig L, Enk C, Bligaard N. Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vitro. Scand J Rheumatol 1988; 17: 255–62
- Shanahan F, Niederlehner A, MacDermott R P, Stenson W F, Kane M G, Targan S. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology 1986; 11: 111–18
- Sheldon P, Grindulis K, Webb C. Sulphasalazine—is its mode of action exerted by immunosuppression of gut associated lymphocytes?. Clin Exp Rheumatol 1987; 5/S-2: F281
- Symmons D PM, Salmon M, Farr M, Bacon P A. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 575–9
- Rubinstein A, Das K M, Melamed J, Murphy R A. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: Effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol 1978; 33: 217–24
- Farr M, Brodrick A, Bacon P A. Plasma and synovial fluid concentrations of sulfasalazine and two of its metabolites in rheumatoid arthritis. Rheumatol Int 1985; 5: 247–51
- Pullar T, Hunter J A, Capell H A. Sulphasalazine in the treatment of rheumatoid arthritis: Relationship of dose and serum levels to efficacy. Br J Rheumatol 1985; 24: 269–76
- Azad Khan A K, Truelove S C, Aronson J K. The disposition and metabolism of sulphasalazine (salicylazosulfapyridine) in man. Br J Clin Pharmacol 1982; 13: 523–8
- Helander S. On the concentrations of some sulfanilamide derivatives in different organs and tissue structures. Acta Physiol Scand 1945, suppl 29